UPMC Western Psychiatric Hospital PGY2 Psychiatric Pharmacy Residency Program

Block Rotations (Six weeks)

• General Adult Psychiatry.
• Comprehensive Recovery Service.
• Emergency Psychiatry.
• Population-Based Psychiatry (e.g. child and adolescent or geriatric).
• Specialized Psychiatry (e.g. consult liaison, neurology, or toxicology).

Longitudinal Rotations (12 months)

• Ambulatory Mental Health Clinic.
• Clinical Consultation.
• Medication Safety.
• Academia and Professional Development.
• Personal Development.
• Inpatient Operations.

Electives (Six weeks)

• Ambulatory Mental Health Clinic.
• Ambulatory Mental Health Clinic – VA.
• Extended Acute Care.
• Substance Use Disorders – WPH.
• Elective rotations available depending upon interest of the resident and availability of the preceptor.

Deliverables

• Research:
  • Completion of major pharmacy resident research project as evidenced by QRC or IRB submission, presentation slides and manuscript.
• Medication Use Evaluation (MUE):
  • Completion of MUE as evidenced by Pharmacy & Therapeutics Advisory & Implementation (PTAI) MUE presentation slides.
• Presentations
  • One (1) UPMC Grand Rounds (known as PULSE) presentation.
  • One (1) Formal case presentation.
  • One (1) Journal Club presentation.
• Service:
  • Two (2) community service activities as evidenced by event reflections.
• Completion of PTAI Committee responsibilities:
  • ADR/Labeling change summary slides.
  • PTAI Newsletter.
  • PTAI Meeting minutes.
• Documentation of completion of all learning experiences within ASHP PGY2 Psychiatry Appendix.
• Obtain the rating of “Achieved for Residency” for 100% of Patient Care objectives.
• Obtain the rating of “Achieved for Residency” for ≥ 80% of ASHP residency objectives where:
  • Any objectives that do not receive the rating of “Achieved” must receive a minimum rating of “Satisfactory Progress.”
  • No remaining objectives may have a rating of "needs improvement" at the end of the residency program.
• Attendance at all unexcused Residency Advisory Committee (RAC) Meetings.

Residency Program Director

• Andreea Temelie, PharmD, BCPP

Residency Program Coordinator

• Marissa Cullen PharmD, BCPP

Preceptors

• Tanya J. Fabian, PharmD, PhD, BCPP
• Christine Clark, PharmD, BCPP
• Marissa Cullen, PharmD, BCPP
• Karen Fielding, PharmD
• Marc Gutowski, PharmD
• Matthew Joseph, PharmD, BCPS
• Ana Lupu, PharmD
• Matthew Kuhn, PharmD
• Megha Patel, PharmD, BCPS
• Katherine Roberts, PharmD
• Emily Thacker, PharmD
• Andreea Temelie, PharmD, BCPP
• Melanie Yabs, PharmD, MS, BCPP

Current Residents

• Kavya Achyutuni, PharmD
• Angeleki Zecopoulos, PharmD

Former Residents and First Positions

• 2025 Residents
  • Michael (Mick) Harrison, PharmD – Acute Care Clinical Psychiatric Pharmacist, Geisinger Health Northeast
  • Hannah Holloway, PharmD – Ambulatory Care Behavioral Health and Pain Management Pharmacist, Geisinger Health System
• 2024 Residents
  • Paige-Dorve Lewis, PharmD – Behavioral Health Pharmacist, SUNY Upstate University Hospital
  • Christine Sun, PharmD, BCPP – Clinical Psychiatric Pharmacist, McLean Hospital
• 2023 Residents
  • Harrison Ferro, PharmD, BCPP – Psychiatric Clinical Pharmacist, VA Medical Center Wilkes-Barre
  • Emily Thacker, PharmD – Psychiatric Clinical Pharmacist, UPMC Western Psychiatric Hospital
• 2022 Residents
  • Dante Delerme, PharmD – Psychiatric Clinical Pharmacist, Kaiser Permanente San Jose Medical Center
  • Zoe Karavolis, PharmD, MPH, BCPP – Clinical Psychiatric Pharmacist, McClean Hospital
• 2021 Resident
  • Andreea Temelie, PharmD, BCPP – Psychiatric Clinical Pharmacist, UPMC Western Psychiatric Hospital
• 2020 Resident
  • Melanie Yabs, PharmD, MS, BCPP – Psychiatric Clinical Pharmacist, UPMC Western Psychiatric Hospital
• 2019 Resident
  • Taylor Dean, PharmD, BCPP – Inpatient Psychiatric Clinical Pharmacist, University of Kansas Health System
• 2018 Resident
  • Jerome (Jerry) Pasquale, PharmD, BCPP – Inpatient Psychiatric Clinical Pharmacist, Mercy St Charles

• Phorcas Deadline: January 2.
• Application Requirements include:
  • Curriculum Vitae.
  • Letter of Intent.
  • Three Letters of Recommendation (one from PGY1 Residency Program Director, one from clinical preceptor with whom resident completed a clinical rotation preferably in area of practice of PGY2).
• Interview requirement (live or virtual): virtual.

Publications

Sun, C., Temelie, A., Goulding, H., Clark, C., Yabs, M., & Fabian, T. (2025). Comparison of Psychiatric Readmission Rates for Child and Adolescent Patients on Long-Acting Injectable Antipsychotics vs. Oral Antipsychotics: A Mirror Study. Journal of Child and Adolescent Psychopharmacology. DOI: 10.1089/cap.2024.0072

Sun C, Temelie A, Goulding H, Clark C, Yabs M, & Fabian T. (2025). Long-acting injectable antipsychotic initiation in child and adolescent patients with psychiatric disorders. J Child Adolesc Psychopharmacol.

Karavolis, Z., Thacker, E., Fabian, T., Douaihy, A., Reynolds, M., Kirisci, L., & Tarter, R. (2024). Pharmacist-implemented intervention to surmount COVID-19 vaccination hesitancy in adults with substance use disorders. American journal of health-system pharmacy. AJHP : official journal of the American Society of Health-System Pharmacists, 81(16), 706–712. https://doi.org/10.1093/ajhp/zxae095

Stutzman, D. L., Leiby, L. E., Temelie, A., Maroney, M., Williams, A. M., Parmentier, B. L., & Payne, G. H. (2023). Role of Board‐Certified Psychiatric Pharmacists in child and adolescent psychiatry. JAACP : Journal of the American College of Clinical Pharmacy. https://doi.org/10.1002/jac5.1880

Karavolis, Z. A., & Roy, P. J. (2022). Adapting low-dose buprenorphine induction to meet patient needs: A pilot study. Drug and alcohol dependence reports, 5, 100104. https://doi.org/10.1016/j.dadr.2022.100104

Winstanley, E. L., Thacker, E. P., Choo, L. Y., Lander, L. R., Berry, J. H., & Tofighi, B. (2022). Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use. Drug and alcohol dependence reports, 5, 100091.

Thacker E. P. (2021). Building bridges to recovery in Appalachia. Journal of the American Pharmacists Association : JAPhA, 61(3), 226–227.

Awards

• Angeleki Zecopoulos, PharmD (PGY2 Class of 2026)
  • UPMC Western Behavioral Health Research and Evidence Based Practice Award for “The Impact of Pharmacist Led AIMS Monitoring Service.
• Hannah Holloway, PharmD (PGY2 Class of 2025)
  • President’s Award for Implementation of Addiction Medicine Pharmacy Consult Service at an Inpatient Psychiatric Hospital.
• Paige Dorve-Lewis, PharmD (PGY2 Class of 2024)
  • American Association of Psychiatric Pharmacists (AAPP) Defining the Future Research Grant Recipient 2023.
• Harrison Ferro, PharmD (PGY2 Class of 2023)
  • AAPP Innovative Practices Award 2025 for Impact of a Pharmacy Mental Health Practitioner on an Inpatient Psychiatry Consultation Liaison Service.
• Zoe Karavolis, PharmD, MPH, BCPP (PGY2 Class of 2022)
  • AAPP New Practitioner Award 2026.
• Andreea Temelie, PharmD, BCPP (PGY2 Class of 2021)
  • Hospital/Health System Association of Pennsylvania (HAP) Excellence in Care Award for “Process and Outcomes for Deprescribing Benzodiazepines in the Outpatient Setting for Adults with Intellectual Disabilities and Autism.”
  • UPMC Western Behavioral Health Medical Director’s Award for Pharmacists: Key Team Members in Identifying and Resolving Medication Errors and Discrepancies During Transitions of Care.
  • UPMC Western Behavioral Health Medical Director’s Award for Deprescribing in Older Adults during Inpatient Psychiatric Hospitalization.